

International Conference on
CANCER THERAPY &
International Conference on
VACCINES & VACCINATION

July 23-24, 2018 | Osaka, Japan

Predictive factors of disease free survival in ovarian clear cell carcinoma in Peru

Vera Juana¹, Motta Rodrigo², Aguilar Sergio², Fernández Ana², Kapsoli María de Carmen¹, Latorre Alan¹, Patiño Karina¹ and Alfaro Daney¹

¹Edgardo Rebagliati Martins Hospital, Peru

²Edgardo Rebagliati Martins Hospital, Peru


Introduction: Ovarian Clear cell carcinoma (OCCC) represents 5-10% of all primary ovarian carcinoma and the median incidence is 23% of all ovarian carcinoma at Rebagliati Hospital, in Peru. It is higher than those reported worldwide.

Methods: Medical records of patients with OCCC were retrospectively reviewed between 2013 and 2016. Descriptive tabulations of the clinical and pathological characteristics of patients. DFS curves were reviewed by the Kaplan-Meier method. The comparisons according to the clinical characteristics were reviewed by the Logrank or Breslow test.

Results: 33 patients were included. The median follow-up was 1.4 years (0.9-1.9 y). 75.8% were older than 45 years, 72.7% underwent optimal surgery. 46.4% had capsule rupture, 9.4% reported lymphovascular tumor emboly, 34.2% necrosis, 60.6% endometriosis and 51.5% peritumoral lymphocytes. 75% of cases presented residual disease less than 1 cm. 60.6% had FIGO I, 9.1% II, 18.2% III and 12.1% IV. 58.5% received adjuvancy with Carboplatin/Paclitaxel and 75% of them completed the 6 courses. Recurrence

in patients who received adjuvant chemotherapy was 18.2% and the most frequent site was at the peritoneal level (57.1%). The rate of DFS at one year was 78.8%. In the univariate analysis, patients with an age <45 years (p <0.001) and a FIGO III-IV clinical stage (p = 0.042) resulted in lower disease-free survival.

Conclusions: Patients with age <45 years and FIGO III-IV could be predictor of poor DFS in OCCC



Biography

Juana Vera, medical surgeon, with a Postgraduate degree in Pathological Anatomy at the National University of San Marcos. Master's Degree in Public Health with a mention in Hospital Management. She works since 2012 at the Surgical Pathology Service of ERMH, being her main activity and interest Gynecological Pathology. In 2014, she completed an internship at the Department of Pathology of the H. Lee Moffitt Cancer Center, Tampa Florida. Member of the Peruvian Association of Pathologists and the Society of Cytology. Regular member of the United States and Canadian Academy of Pathology and the International Academy of Pathology.

juanaveravera@gmail.com

Notes: